Biocon Trastuzumab
- All
- News
-
Biocon's Breast Cancer Biosimilar Gets USFDA Panel Nod, Shares Surge
In a regulatory filing, Biocon said the committee voted 16-0 in support of eligible indications of the reference product.
-
Biocon's Cancer Drug Accepted For Review, Shares Hit 52-Week High
Biocon shares jumped 5 per cent to their 52-week high on Friday after the drugmaker announced that the European regulator has accepted for review a breast cancer biosimilar jointly developed with Mylan. Biocon and American-Dutch Mylan are exclusive partners on a broad portfolio of biosimilars and insulin analogs.
-
European Medicines Agency Accepts Mylan, Biocon Biosimilar For Review
Mylan and Biocon anticipate that this may be the first marketing authorisation application (MAA) for a Trastuzumab biosimilar accepted by the EMA for review, it added.
-
Biocon Hits 52-Week High On Positive Trial Results Of Cancer Drug
Analysts say the new drug could be a big revenue opportunity for Biocon.
-
Biocon's Breast Cancer Biosimilar Gets USFDA Panel Nod, Shares Surge
In a regulatory filing, Biocon said the committee voted 16-0 in support of eligible indications of the reference product.
-
Biocon's Cancer Drug Accepted For Review, Shares Hit 52-Week High
Biocon shares jumped 5 per cent to their 52-week high on Friday after the drugmaker announced that the European regulator has accepted for review a breast cancer biosimilar jointly developed with Mylan. Biocon and American-Dutch Mylan are exclusive partners on a broad portfolio of biosimilars and insulin analogs.
-
European Medicines Agency Accepts Mylan, Biocon Biosimilar For Review
Mylan and Biocon anticipate that this may be the first marketing authorisation application (MAA) for a Trastuzumab biosimilar accepted by the EMA for review, it added.
-
Biocon Hits 52-Week High On Positive Trial Results Of Cancer Drug
Analysts say the new drug could be a big revenue opportunity for Biocon.
